Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesRecurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Journal of Infection, 06/10/09
Johnson S et al. - Current guidelines recommend that the first recurrent episode be treated with the same agent (i.e., metronidazole or vancomycin) used for the index episode. A reasonable strategy for managing a subsequent episode involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI include vancomycin with adjunctive treatments, such as Saccharomyces boulardii, rifaximin “chaser” therapy after vancomycin, nitazoxanide, fecal transplantation, and intravenous immunoglobulin. New treatment agents that are active against C. difficile, but spare critical components of the normal flora, may decrease the incidence of recurrent CDI.
Related Articles
Toxigenic Clostridium difficile colonization in children
Journal of Pediatric Infectious Diseases, 10/30/09
Relevance Score: 68%
Molecular Epidemiology of Clostridium difficile over the Course of 10 Years in a Tertiary Care Hospital
Clinical Infectious Diseases, 10/16/09
Relevance Score: 67%
Clostridium difficile-related death rates in Texas 1999-2005
Journal of Infection, 10/06/09
Relevance Score: 67%
Bacteriophage-Mediated Toxin Gene Regulation in Clostridium difficile
Journal of Virology, 11/09/09
Relevance Score: 66%
Use of International Classification of Diseases, Ninth Revision, Clinical Modification Codes and Medication Use Data to Identify Nosocomial Clostridium difficile Infection
Infection Control and Hospital Epidemiology, 10/14/09
Relevance Score: 66%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Acquired activation of the Akt/COX-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis
Molecular Pharmacology, 12/04/09
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B
International Journal of Infectious Diseases, 12/04/09
Today in GI Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
A systematic review of serologic tests in the diagnosis of necrotizing enterocolitis
Journal of Pediatric Surgery, 12/04/09
chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease
Alimentary Pharmacology and Therapeutics, 12/03/09
Article Search
Sponsor